{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration+Sensitive+Prostate+Cancer+%28mCSPC%29",
    "query": {
      "condition": "Metastatic Castration Sensitive Prostate Cancer (mCSPC)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration+Sensitive+Prostate+Cancer+%28mCSPC%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:52:18.312Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04666129",
      "title": "Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer",
        "Metastatic Castration-Sensitive Prostate Cancer",
        "Non-Metastatic Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-18",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666129"
    },
    {
      "nct_id": "NCT04497844",
      "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate (AA)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 696,
      "start_date": "2020-09-23",
      "completion_date": "2027-11-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 53,
      "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04497844"
    },
    {
      "nct_id": "NCT07028853",
      "title": "This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration Sensitive Prostate Cancer (mCSPC)",
        "Hormone Sensitive Prostate Cancer",
        "Prostate Cancer",
        "Cancer of the Prostate"
      ],
      "interventions": [
        {
          "name": "Mevrometostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1000,
      "start_date": "2025-09-28",
      "completion_date": "2034-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 96,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 69 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07028853"
    },
    {
      "nct_id": "NCT06429813",
      "title": "Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Castrate Sensitive Prostate Cancer",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Home-Based Exercise Intervention - Walking",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Home-Based Exercise Intervention - HIIT Cycling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Paul Viscuse",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2024-07-26",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06429813"
    },
    {
      "nct_id": "NCT06151418",
      "title": "A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Novel hormonal therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2313,
      "start_date": "2023-11-22",
      "completion_date": "2024-04-23",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06151418"
    },
    {
      "nct_id": "NCT07086651",
      "title": "A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Castration Sensitive Prostate Cancer (mCSPC)",
        "Cancer of the Prostate",
        "Prostate Neoplasms",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1300,
      "start_date": "2025-07-21",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07086651"
    },
    {
      "nct_id": "NCT04887506",
      "title": "TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer",
        "Metastatic Castration-sensitive Prostate Cancer",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "TAVT-45",
          "type": "DRUG"
        },
        {
          "name": "Zytiga",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tavanta Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 107,
      "start_date": "2021-05-05",
      "completion_date": "2022-10-20",
      "has_results": true,
      "last_update_posted_date": "2024-01-16",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 13,
      "location_summary": "Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04887506"
    },
    {
      "nct_id": "NCT04729114",
      "title": "A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Metastatic Castration-sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PRL-02 injection",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 174,
      "start_date": "2021-06-14",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04729114"
    },
    {
      "nct_id": "NCT06120491",
      "title": "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Saruparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 1800,
      "start_date": "2023-11-21",
      "completion_date": "2031-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 118,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 98 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06120491"
    },
    {
      "nct_id": "NCT05884398",
      "title": "A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castrate-sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Androgen-deprivation Therapy (ADT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 420,
      "start_date": "2023-08-31",
      "completion_date": "2028-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-05-22T04:52:18.312Z",
      "location_count": 46,
      "location_summary": "Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05884398"
    }
  ]
}